menu
    • menu

    Company profile for Henlius

    NEW Drugs in Dev: 1
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are a leading biopharmaceutical company in China focusing on oncology and autoimmune diseases with the vision to offer high-quality, affordable and innovative biologics for patients worldwide. Founded in 2010 and headquartered in Shanghai, we have built an integrated and efficient global R&D platform with key facilities in Shanghai, Taipei and California collaborating with each other to ensure the highly productive and cost...
    We are a leading biopharmaceutical company in China focusing on oncology and autoimmune diseases with the vision to offer high-quality, affordable and innovative biologics for patients worldwide. Founded in 2010 and headquartered in Shanghai, we have built an integrated and efficient global R&D platform with key facilities in Shanghai, Taipei and California collaborating with each other to ensure the highly productive and cost-efficient R&D processes. We established the first manufacturing facility featuring the core technology of single-use bioreactors in Shanghai Caohejing Hi-Technology Park in 2016.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    HenliusChina Flag
    Country
    Country
    China
    Address
    Address
    9/F, Innov Tower, Zone A, No. 1801 Hongmei Road, Xuhui District, Shanghai
    Telephone
    Telephone
    021-33395800
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.henlius.com/en/company-profile.html
    Linkedin
    Linkedin
    https://in.linkedin.com/company/henlius
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Arvo

    Arvo

    Not Confirmed

    envelop Contact Supplier

    Arvo

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Henlius Doses First Patient in Next-Gen Tetra-Specific Platform
    Henlius Doses First Patient in Next-Gen Tetra-Specific Platform

    30 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7257131

    FIRSTWORD PHARMA
    30 Apr 2026
    Share Share
    Henlius Completes Phase 2/3 Trial Of Pimurutamab (HLX07)
    Henlius Completes Phase 2/3 Trial Of Pimurutamab (HLX07)

    24 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7207846

    FIRSTWORD PHARMA
    24 Apr 2026
    Share Share
    Henlius: 2025 Revenue, Profit Growth & Key Innovation Advances
    Henlius: 2025 Revenue, Profit Growth & Key Innovation Advances

    20 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/henlius-reports-2025-results-sustained-growth-in-both-revenue-and-profit-advancing-innovation-validation-and-global-operations-302719821.html

    PR NEWSWIRE
    20 Mar 2026
    Share Share
    Inside Henlius' Global Growth Strategy
    Inside Henlius' Global Growth Strategy

    02 Feb 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/sponsored/inside-henlius-global-growth-strategy

    FIERCE BIOTECH
    02 Feb 2026
    Share Share
    Henlius CEO To Present Keynote At JPM 2026
    Henlius CEO To Present Keynote At JPM 2026

    23 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/henlius-ceo-dr-jason-zhu-to-deliver-a-keynote-presentation-at-jpm-2026-302648774.html

    PR NEWSWIRE
    23 Dec 2025
    Share Share
    FDA Approves POHERDY® as First PERJETA Biosimilar
    FDA Approves POHERDY® as First PERJETA Biosimilar

    17 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251117955804/en/Henlius-and-Organon-Announce-US-FDA-Approval-of-POHERDY-pertuzumab-dpzb-the-First-PERJETA-pertuzumab-Biosimilar-in-the-US

    BUSINESSWIRE
    17 Nov 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search